quinazolines has been researched along with 1,5-dihydro-7-(1-piperidinyl)-imidazo(2,1-b)quinazolin-2(3h)-one in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (47.83) | 18.7374 |
| 1990's | 10 (43.48) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashida, S; Sakuma, K | 1 |
| Isaka, Y; Kamada, T; Kambayashi, J; Kawasaki, T; Kimura, K; Mori, T; Sakon, M; Shiba, E; Watase, M | 1 |
| Gray, SJ; Heptinstall, S | 1 |
| Amemiya, A; Chang-Chun, C; Kaneko, M; Kawashima, Y; Kuratani, T; Matsuda, H; Nishimura, M; Sakagoshi, N; Sawa, Y | 1 |
| Osada, Y; Tanaka, NG; Tohgo, A | 1 |
| Hashimoto, H; Ishii, K; Satoh, K; Taira, N | 1 |
| Chiba, S; Nakane, T | 1 |
| Chiba, S; Haruta, K; Homma, N; Horiuchi, A; Iwatsuki, K; Yonekura, H | 1 |
| Kawai, C; Murohara, Y; Takatsu, Y; Yui, Y | 1 |
| Ball, J; Greaves, M; Jackson, C; Lawry, J; Peel, J; Preston, FE | 1 |
| Akahane, K; Chiba, S; Furukawa, Y; Haniuda, M; Karasawa, Y | 1 |
| Etherington, MD; O'Brien, JR; Salmon, GP | 1 |
| Itoh, T; Kambayashi, J; Mori, T; Sakon, M; Tsujinaka, T; Uemura, Y | 1 |
| Matsumoto, M | 1 |
| Kambayashi, J; Kawasaki, T; Mori, T; Sakon, M; Suga, K | 1 |
| Ono, K; Takegoshi, T; Tanaka, M; Yamada, M | 1 |
| Kawai, M; Kurihara, S; Tanaka, T | 1 |
| Yano, S | 1 |
| Glenn, J; Hardy, E; Heptinstall, S; Horn, EH; Rubin, PC | 1 |
| Hakusui, H; Ishikawa, F; Tanaka, M | 1 |
| Glenn, JR; Heptinstall, S | 1 |
| Kondo, S; Kubota, S; Mukudai, Y; Sugahara, T; Takigawa, M; Tanaka, N; Yosimichi, G | 1 |
| Glenn, JR; Heptinstall, S; Iyu, D; White, AE | 1 |
1 review(s) available for quinazolines and 1,5-dihydro-7-(1-piperidinyl)-imidazo(2,1-b)quinazolin-2(3h)-one
| Article | Year |
|---|---|
Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Platelets; Cyclic AMP; Papaverine; Platelet Aggregation; Quinazolines; Rats; Serotonin | 1992 |
22 other study(ies) available for quinazolines and 1,5-dihydro-7-(1-piperidinyl)-imidazo(2,1-b)quinazolin-2(3h)-one
| Article | Year |
|---|---|
Phosphodiesterase inhibitors as antiplatelet agents in vascular surgery.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Animals; Cilostazol; Female; Humans; In Vitro Techniques; Male; Middle Aged; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Quinazolines; Rabbits; Tetrazoles; Vascular Surgical Procedures | 1992 |
Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine Diphosphate; Adenylyl Cyclases; Blood Platelets; Cyclic AMP; Dinoprostone; Humans; Imidazoles; In Vitro Techniques; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Quinazolines | 1991 |
Effect of a cyclic adenosine monophosphate phosphodiesterase inhibitor, DN-9693, on myocardial reperfusion injury.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Coronary Circulation; Myocardial Reperfusion Injury; Myocardium; Phosphodiesterase Inhibitors; Quinazolines; Rabbits | 1991 |
Inhibitory effects of DN-9693 on platelet-enhanced tumor cell attachment to cultured endothelium.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Platelets; Calcium; Cells, Cultured; Endothelium, Vascular; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Neoplasms, Experimental; Platelet Activation; Platelet Aggregation Inhibitors; Pulmonary Artery; Quinazolines; Tumor Cells, Cultured | 1990 |
Comparison of vasodilator effects of DN-9693, a selective inhibitor of cyclic AMP phosphodiesterase, and isobutylmethylxanthine, a non-selective one, in dogs.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antineoplastic Agents; Coronary Circulation; Dogs; Female; Femur; Male; Myocardium; Oxygen Consumption; Quinazolines; Regional Blood Flow; Renal Circulation; Splanchnic Circulation; Theophylline; Vasodilator Agents | 1987 |
Effects of DN-9693, a selective inhibitor of cyclic AMP phosphodiesterase, in isolated and perfused canine large coronary arteries.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Aminophylline; Animals; Coronary Vessels; Dogs; Dose-Response Relationship, Drug; Female; In Vitro Techniques; Male; Quinazolines; Vasodilation | 1988 |
Effects of DN-9693, a synthesized phosphodiesterase inhibitor, on pancreatic exocrine secretion in dogs.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Atropine; Cholecystokinin; Cimetidine; Dogs; Dose-Response Relationship, Drug; Female; Male; Pancreas; Pancreatic Juice; Papaverine; Phentolamine; Phosphodiesterase Inhibitors; Propranolol; Quinazolines; Secretin; Sulpiride; Theophylline | 1989 |
[The mode of action and clinical applications of phosphodiesterase inhibitors as anti-platelet drugs].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cilostazol; Coronary Disease; Coronary Thrombosis; Cyclic AMP; Dipyridamole; Fibrinolytic Agents; Humans; Phosphodiesterase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinazolines; Tetrazoles | 1989 |
DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine Triphosphate; Antibodies, Monoclonal; Cyclic AMP; Humans; In Vitro Techniques; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Quinazolines; Ristocetin; Serotonin; Thromboxane B2 | 1989 |
Cardiovascular responses to a newly developed phosphodiesterase inhibitor, DN-9693 [7-pyperidinyl-1,2,3,5-tetrahydroimidazo (2,1-b)-quinazolin-2-one.HCl] in dog cross-circulated atrial and ventricular preparations.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Pressure; Cross Circulation; Dogs; Female; Heart; Heart Rate; Imidazoles; Male; Myocardial Contraction; Phosphodiesterase Inhibitors; Quinazolines | 1989 |
DN.9693, a phosphodiesterase inhibitor, compared with prostaglandin E1 and prostacyclin in four platelet "function" tests.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Alprostadil; Clot Retraction; Epoprostenol; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Quinazolines | 1988 |
Clinical application of a new in vitro bleeding time device on surgical patients.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aspirin; Bleeding Time; Epoprostenol; Hemorrhage; Hemostasis; Humans; Liver Cirrhosis; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Quinazolines; Skin; Thrombocytopenia; Ticlopidine | 1988 |
[Behavior of platelets and leukocytes on the luminal surface of small caliber prosthetic grafts].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aspirin; Blood Vessel Prosthesis; Cell Adhesion; Dogs; Graft Occlusion, Vascular; Leukocytes; Microscopy, Electron, Scanning; Platelet Adhesiveness; Polytetrafluoroethylene; Quinazolines; Thrombosis | 1988 |
Phosphorylation of phosphoinositides in human platelets.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminoquinolines; Blood Platelets; Bucladesine; Calcium; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Epoprostenol; Humans; Phosphatidic Acids; Phosphatidylinositol Phosphates; Phosphatidylinositols; Phosphorus Radioisotopes; Phosphorylation; Quinazolines | 1986 |
Determination of 7-piperidino-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (DN-9693) in human plasma and urine by high-performance liquid chromatography with electrochemical detection: application to studies on disposition of DN-9693 in healthy human
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Kinetics; Male; Quinazolines | 1987 |
Effects of a new inotropic drug (DN-9693) on Ca2+ transients and contraction in ferret ventricular muscles.
Topics: Animals; Calcium; Cardiotonic Agents; Cyclic AMP; Dose-Response Relationship, Drug; Ferrets; In Vitro Techniques; Myocardial Contraction; Phosphodiesterase Inhibitors; Quinazolines | 1995 |
[Effects of platelet aggregating inhibitor on pulmonary metastases of tumor cells after surgical resection].
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Transplantation; Platelet Aggregation Inhibitors; Quinazolines; Rats; Rats, Inbred Strains | 1993 |
Magnesium modifies the responses of platelets to inhibitory agents which act via cAMP.
Topics: Blood Platelets; Colforsin; Cyclic AMP; Drug Interactions; Female; Humans; Iloprost; Magnesium; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin D2; Quinazolines; Signal Transduction | 1995 |
Isolation and identification of seven metabolites of a water-soluble platelet aggregation inhibitor in rat urine.
Topics: Animals; Chromatography, High Pressure Liquid; Fourier Analysis; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Molecular Structure; Platelet Aggregation Inhibitors; Quinazolines; Rats; Rats, Wistar; Solubility; Water | 1995 |
Evidence that adenosine diphosphate can activate adenylate cyclase via conversion to adenosine in platelet-rich plasma containing magnesium.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Adenylyl Cyclases; Colforsin; Cyclic AMP; Enzyme Activation; Humans; Iloprost; Magnesium; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Receptors, Purinergic P2; Reference Values | 1998 |
Novel angiogenic inhibitor DN-9693 that inhibits post-transcriptional induction of connective tissue growth factor (CTGF/CCN2) by vascular endothelial growth factor in human endothelial cells.
Topics: Angiogenesis Inhibitors; Cell Proliferation; Cells, Cultured; Connective Tissue Growth Factor; Endothelium, Vascular; Gene Expression Regulation; Half-Life; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Promoter Regions, Genetic; Quinazolines; RNA Processing, Post-Transcriptional; RNA, Messenger; Umbilical Veins; Vascular Endothelial Growth Factor A | 2006 |
PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
Topics: Acrylamides; Blood Platelets; Cell Adhesion Molecules; Colforsin; Cyclic AMP; Dinoprostone; Humans; Microfilament Proteins; Naphthalenes; Phenylbutyrates; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin Antagonists; Quinazolines; Receptors, G-Protein-Coupled; Receptors, Prostaglandin E, EP3 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Sulfones | 2012 |